P3.02c-097 Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Elderly patients with advanced non-small-cell lung cancer.
Advanced non-small cell lung cancer (NSCLC) in elderly patients is an increasingly common problem which the practitioner of oncology must face. There is no consensus on the cut-off age for defining the elderly. However, 70 years may be the most appropriate because the incidence of age-related changes starts to increase after this boundary. Important concerns in evaluating the treatment of elder...
متن کاملSystemic Therapy Options for Non–Small-Cell Lung Cancer in Patients with a Poor Performance Status
Discuss appropriate management strategies for patients with advanced non-small cell lung cancer (NSCLC) who have a poor performance status (PS). Explore the role of concurrent chemotherapy for locally advanced NSCLC in patients with a PS of 2. Review the single-agent, doublet, and molecularly targeted therapies under investigation for patients with advanced NSCLC with a poor PS. Appreciate the ...
متن کاملMulticentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
OBJECTIVE Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurrent non-squamous NSCLC. METHODS In this multicentre phase II study, patients with advanced or re...
متن کاملA phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).
BACKGROUND Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC. PATIENTS AND METHODS Older patients [≥ 65 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2] or younger patients (performance ...
متن کاملPhase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.
BACKGROUND Elderly patients with advanced non-small-cell lung cancer (NSCLC) with poor performance status (PS) are a special population requiring particular attention. Single-agent oral vinorelbine could be an attractive option. PATIENTS AND METHODS A total of 43 patients with stage IIIB-IV NSCLC and Eastern Cooperative Oncology Group (ECOG) PS of two or more with good functional status were ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1893